Recently, some new therapies targeting epidermal growth factor receptor (EGFR), v-raf murine sarcoma viral oncogene homologue B (BRAF), rat sarcoma (RAS), as well as programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have been trialed to treat ATCs [5,6], although the overall survival rate of ATC patients remains almost unchanged [2]. This evidence concerns the gene CD274 and Ehlers-Danlos syndrome, musculocontractural type.